Novel Agents in CML Therapy:
Tyrosine Kinase Inhibitors and Beyond
Junia V. Melo (2) and Charles Chuah (1)

Press Release Source: Novartis Pharmaceuticals UK Ltd

Data Shows Longest Ever Survival for Patients With Life-Threatening Leukaemia Treated With Breakthrough Treatment
Monday December 8, 5:00 pm ET
- 86 Percent of Patients With Ph+ Chronic Myeloid Leukaemia
Treated With Breakthrough Treatment Glivec(R) are Alive After Seven Years(1)
- Treatment Shown to Slow Disease Progression: Only one Patient
out of 317 Experienced Disease Progression Between Year Six and Seven of
Treatment(1)
- Data Demonstrate Longest Overall Survival Observed to Date in
This Disease Area

....read full press release here

Why Gleevec-type Drugs Control, But Do Not Eradicate, Leukemia

ScienceDaily (Dec. 11, 2008) — Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.

New Approach To Help Control Drug Resistance In Leukemia Identified

ScienceDaily (Mar. 25, 2008) — Oregon Health & Science University Cancer Institute researchers have found that an experimental drug known as SGX393 is effective against Gleevec-resistant chronic myeloid leukemia (CML).

Combination Of Two Novel Anti-cancer Agents May Help Fight CML Resistant To Current Therapy

ScienceDaily (June 1, 2008) — Virginia Commonwealth University Massey Cancer Center researchers have identified that a combination of novel anti-cancer compounds is able to kill chronic myelogenous leukemia cells previously resistant to conventional forms of therapy.

Drug Shown To Be Clinically Active Against Multiple Target Mutations In Two Types Of Leukemia And Myeloproliferative Disorders

ScienceDaily (Dec. 21, 2006) — Researchers at The University of Texas M. D. Anderson Cancer Center report that MK-0457 (VX-680), a novel multi-kinase inhibitor, is clinically active against multiple target mutations in two types of leukemia and myeloproliferative disorders, and produces few side effects for patients.

Vaccine Improves Event-free Survival For Leukemia Patients

ScienceDaily (Dec. 11, 2007) — Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

Dasatinib, Nilotinib Show Strong Early Results As Frontline Therapy For Chronic Myelogenous Leukemia

ScienceDaily (Dec. 10, 2007) — Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

4 Nov 2008 : Column 131

NHS Patients (Access to Medicines)
4.7 pm

EUTOS.